Octave Bioscience Receives Grant to Develop World's First Blood Test for Multiple Sclerosis Progression
核心洞察
Octave Bioscience (搜索) has been awarded a Valhalla Foundation (搜索) grant to develop the Multiple Sclerosis (搜索) Disease Progression (MSDP) Test, the world's first biomarker blood test for MS progression.
The MSDP Test (搜索) will build on Octave's existing MS Disease Activity Test and use multi-protein biomarkers with AI-driven algorithms to track disease progression over time.
The test addresses a critical unmet need in MS care, as physicians currently rely on subjective assessments and infrequent imaging that often miss disease changes until disability has advanced.
Octave Bioscience (搜索), a commercial-stage precision care company focused on neurodegenerative diseases, has secured funding from the Valhalla Foundation (搜索) to advance development of what would be the world's first biomarker blood test for multiple sclerosis (搜索) progression. The Multiple Sclerosis Disease Progression (MSDP) Test represents a significant step forward in addressing one of the most challenging aspects of MS care.
Building on Existing Success
The MSDP Test (搜索) builds upon Octave's established MS Disease Activity (MSDA) Test, which is described as the first validated AI-enabled multi-protein blood test for MS. The new progression test will extend Octave's capabilities in precision neurology by providing a complementary solution to their existing disease activity monitoring platform.
The Valhalla Foundation (搜索) grant will specifically fund the identification of individual proteins and development of multi-analyte biomarker models, advancing the MSDP Test (搜索) toward commercial viability. Octave plans to collaborate with leading academic partners worldwide, using advanced assays to study proteins in MS patients, with findings intended for publication in a peer-reviewed journal.
Addressing Critical Unmet Medical Need
According to the company, the MSDP Test (搜索) tackles one of the most urgent unmet needs in MS care: the lack of reliable tools to measure or predict disease progression. Currently, physicians and patients must rely on subjective assessments and infrequent imaging, which often leaves critical disease changes undetected until disability has already advanced.
"Octave is poised to tackle one of the most critical problems facing the MS field, that of reliably measuring the biology of progressive disease," said Dr. Jennifer Graves, Senior Medical Advisor at Octave and Professor of Neurosciences at UC San Diego. "If you can measure something, you can target it. Octave's delivery of a progressive MS biomarker test will fuel therapeutic development and improved management of the most challenging aspects of MS."
Test Design and Clinical Applications
The MSDP Test (搜索) will combine multi-protein biomarkers with AI-driven algorithms to deliver objective scores that track progression over time. This approach is designed to empower physicians to make earlier and more confident treatment decisions. Delivered as a simple blood test, the MSDP Test is being developed for all MS patients, including those with Relapsing Remitting MS (搜索) (RRMS), Primary Progressive MS (搜索) (PPMS), and Secondary Progressive MS (搜索) (SPMS).
Dr. Graves emphasized the timing of this development, noting "Valhalla's strategic investment is critically timed to advance a biomarker test in the setting of an ever-increasing number of patients aging with MS and facing progressive disease."
Foundation Support and Vision
Sara Allan, President of the Valhalla Foundation (搜索), highlighted the potential impact of this research: "Octave's research to discover and validate unique biomarkers for MS progression has the potential to deliver a transformative measurement tool that provides critical insights for both drug developers and physicians to fundamentally improve the lives of patients."
The Valhalla Foundation (搜索) focuses on driving measurable improvement in health outcomes through strategic investments in medical research and talent, among other program areas. The foundation prioritizes working collaboratively with other funders to expand resources for compelling ideas and build strong evidence of impact.
Company Background
Octave Bioscience (搜索) is a commercial-stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases. Beyond multiple sclerosis (搜索), the company is also working on Parkinson's Disease (搜索) solutions in partnership with the Michael J. Fox Foundation (搜索). The company's comprehensive testing solutions aim to provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes.